Hi Hershamboy, The CEO is not the issue. He did not re-issue the options to ex Directors by himself. Wake up....there a 2 others directors on the Board whom were also involved in the decision. Perhaps bagging the CEO is convenient for you in the absence of deeper understanding. You need to ask yourself or perhaps find out from the company who wanted to reinstate them and who didn't/dissented (if anyone). Has anyone asked about the progress of the studies that Professor Bruce Thompson is conducting? This is his one responsibility for the company and as yet we have had no details at the specific number of patients that have been tested in his studies. Yes he came out on video and said he would have both studies completed by the end of the year however how many have been tested so far, what will be the total number of patients tested and will it be statistical relevant?!? How is it that other medtech companies with significantly inferior products can get plenty of patients for their studies and complete them relatively quickly whereas Professor Thompson through Eastern Health is taking significantly longer. I have no doubt progress is being made however not nearly quickly enough for what he stated would be the case (6 weeks) back in June. The announcement todays shows that India is progressing quickly and every person, resource in the Company should be completely focused on this market in the short term. However Professor Thompson also needs to be held accountable to his primary task of completing 2 studies (with statistical relevance) as quickly as possible and publishing them in the medical journal which has not been achieved.
RSH Price at posting:
8.5¢ Sentiment: Buy Disclosure: Held
